Skip to main content
SpringerLink
Log in

Antipsychotics

  • Chapter
  • First Online:
Understanding Suicide

  • 2248 Accesses

Abstract

Suicide is a fatal outcome that frequently occurs in people suffering from schizophrenia and other psychoses. Lifetime rate of suicide in patients with schizophrenia has been reported to be around 10 %. Suicidal risk in schizophrenia is mainly related to affective symptoms, previous suicidal attempts, number of psychiatric admissions, younger age at onset, substance misuse or dependence, closeness to illness onset, male sex, and period during or following psychiatric discharge. Except for clozapine, no antipsychotic treatment has been established to be useful in reducing suicidality in patients with schizophrenia, being the only drug whose potential anti-suicidal properties have been officially recognized by the FDA in the USA. However, in light of recent data, the anti-suicidal effect of antipsychotics could be extended to other second-generation antipsychotics (mainly olanzapine and risperidone). The anti-suicidal effect of antipsychotics in non-psychotic patients needs to be further demonstrated. Timely and appropriate use of antipsychotic agents, bearing in mind adverse events, might contribute to a net positive effect on suicidality in psychotic and perhaps even in non-psychotic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aguilar EJ, Siris SG (2007) Do antipsychotic drugs influence suicidal behavior in schizophrenia? Psychopharmacol Bull 40(3):128–142

    PubMed  Google Scholar 

  • Ainiyet B, Rybakowski JK (2014) Suicidal behavior in schizophrenia may be related to low lipid levels. Med Sci Monit: Int Med J Exp Clin Res 20:1486–1490

    Article  CAS  Google Scholar 

  • Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E (2003) Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 60(1):47–55

    Article  CAS  PubMed  Google Scholar 

  • Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S et al (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 11:CD006633

    PubMed  Google Scholar 

  • Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19(3):609–618

    Article  CAS  PubMed  Google Scholar 

  • Awad AG, Voruganti LN (2004) Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18(13):877–893

    Article  CAS  PubMed  Google Scholar 

  • Awad AG, Voruganti LN (2005) Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand Suppl 427:6–13

    Article  PubMed  Google Scholar 

  • Awad AG, Voruganti LN (2013) The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs 27(8):625–636

    Article  PubMed  Google Scholar 

  • Barak Y, Mirecki I, Knobler HY, Natan Z, Aizenberg D (2004) Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology 175(2):215–219

    Article  CAS  PubMed  Google Scholar 

  • Battaglia J, Wolff TK, Wagner-Johnson DS, Rush AJ, Carmody TJ, Basco MR (1999) Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. Int Clin Psychopharmacol 14(6):361–372

    Article  CAS  PubMed  Google Scholar 

  • Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 59(3):103–107

    Article  CAS  PubMed  Google Scholar 

  • Brotman MA, Fergus EL, Post RM, Leverich GS (2000) High exposure to neuroleptics in bipolar patients: a retrospective review. J Clin Psychiatry 61(1):68–72; quiz 3

    Article  CAS  PubMed  Google Scholar 

  • Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71–93

    Article  PubMed  PubMed Central  Google Scholar 

  • Caldwell CB, Gottesman II (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16(4):571–589

    Article  CAS  PubMed  Google Scholar 

  • Challis S, Nielssen O, Harris A, Large M (2013) Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis. Acta Psychiatr Scand 127(6):442–454

    Article  CAS  PubMed  Google Scholar 

  • Chapman CL, Mullin K, Ryan CJ, Kuffel A, Nielssen O, Large MM (2015) Meta-analysis of the association between suicidal ideation and later suicide among patients with either a schizophrenia spectrum psychosis or a mood disorder. Acta Psychiatr Scand 131(3):162–173

    Article  CAS  PubMed  Google Scholar 

  • Cheng KK, Leung CM, Lo WH, Lam TH (1990) Risk factors of suicide among schizophrenics. Acta Psychiatr Scand 81(3):220–224

    Article  CAS  PubMed  Google Scholar 

  • Cheng HM, Park JH, Hernstadt D (2013) Akathisia: a life-threatening side effect of a common medication. BMJ Case Rep 2013:bcr2012007713

    Google Scholar 

  • Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 61(5):329–334

    Article  CAS  PubMed  Google Scholar 

  • Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J et al (2001) Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 52(11):1510–1514

    Article  CAS  PubMed  Google Scholar 

  • Cohen S, Leonard CV, Farberow NL, Shneidman ES (1964) Tranquilizers and suicide in the schizophrenic patient. Arch Gen Psychiatry 11:312–321

    Article  CAS  PubMed  Google Scholar 

  • De Alarcon R, Carney MW (1969) Severe depressive mood changes following slow-release intramuscular fluphenazine injection. Br Med J 3(5670):564–567

    Article  PubMed  PubMed Central  Google Scholar 

  • De Hert M, Correll CU, Cohen D (2010) Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 117(1):68–74

    Article  PubMed  Google Scholar 

  • Di Fiorino M, Montagnani G, Trespi G, Kasper S (2014) Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. Int Clin Psychopharmacol 29(3):166–176

    Article  PubMed  Google Scholar 

  • Ernst CL, Goldberg JF (2004) Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12(1):14–41

    PubMed  Google Scholar 

  • Fazel S, Wolf A, Palm C, Lichtenstein P (2014) Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry 1(1):44–54

    Article  PubMed  PubMed Central  Google Scholar 

  • Fleischhacker WW, Kane JM, Geier J, Karayal O, Kolluri S, Eng SM et al (2014) Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. J Clin Psychiatry 75(3):e184–e190

    Article  PubMed  Google Scholar 

  • Gaertner I, Gilot C, Heidrich P, Gaertner HJ (2002) A case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. Pharmacopsychiatry 35(2):37–43

    Article  CAS  PubMed  Google Scholar 

  • Gentile S (2013) Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy 33(10):1087–1106

    Article  CAS  PubMed  Google Scholar 

  • Gonzalez-Rodriguez A, Molina-Andreu O, Navarro Odriozola V, Gasto Ferrer C, Penades R, Catalan R (2014) Suicidal ideation and suicidal behaviour in delusional disorder: a clinical overview. Psychiatry J 2014:834901

    Article  PubMed  PubMed Central  Google Scholar 

  • Harkavy-Friedman JM, Kimhy D, Nelson EA, Venarde DF, Malaspina D, Mann JJ (2003) Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. J Clin Psychiatry 64(8):871–874

    Article  PubMed  Google Scholar 

  • Haukka J, Tiihonen J, Harkanen T, Lonnqvist J (2008) Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf 17(7):686–696

    Article  PubMed  Google Scholar 

  • Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards G et al (2006) Lifetime suicide rates in treated schizophrenia: 1875–1924 and 1994–1998 cohorts compared. Br J Psychiatry: J Ment Sci 188:223–228

    Article  CAS  Google Scholar 

  • Hearon BA, Garner L, Beard C, Bjorgvinsson T (2015) Predictors of suicidality among patients with psychotic disorders in a partial hospital treatment program. Suicide Life Threat Behav. doi:10.1111/sltb.12165. [Epub ahead of print]

    Google Scholar 

  • Heila H, Isometsa ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lonnqvist JK (1999) Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry 60(3):200–208

    Article  CAS  PubMed  Google Scholar 

  • Hennen J, Baldessarini RJ (2005) Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 73(2–3):139–145

    Article  PubMed  Google Scholar 

  • Herings RM, Erkens JA (2003) Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 12(5):423–424

    Article  PubMed  Google Scholar 

  • Hogan TP, Awad AG (1983) Pharmacotherapy and suicide risk in schizophrenia. Can J Psychiatry 28(4):277–281, Revue canadienne de psychiatrie

    CAS  PubMed  Google Scholar 

  • Huber CG, Smieskova R, Schroeder K, Studerus E, Harrisberger F, Aston J et al (2014) Evidence for an agitated-aggressive syndrome predating the onset of psychosis. Schizophr Res 157(1–3):26–32

    Article  PubMed  Google Scholar 

  • Hussar AE (1962) Effect of tranquilizers on medical morbidity and mortality in a mental hospital. JAMA 179:682–686

    Article  CAS  PubMed  Google Scholar 

  • Johnson DA, Pasterski G, Ludlow JM, Street K, Taylor RD (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67(5):339–352

    Article  CAS  PubMed  Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63(10):1079–1087

    Article  CAS  PubMed  Google Scholar 

  • Kasckow J, Felmet K, Zisook S (2011) Managing suicide risk in patients with schizophrenia. CNS Drugs 25(2):129–143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keck PE Jr, Strakowski SM, McElroy SL (2000) The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 61(Suppl 3):4–9

    CAS  PubMed  Google Scholar 

  • Khan A, Khan SR, Leventhal RM, Brown WA (2001) Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database. Am J Psychiatry 158(9):1449–1454

    Article  CAS  PubMed  Google Scholar 

  • Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, Hakkinen U, Isohanni M, Hakko H (2013) Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 150(1):274–280

    Article  PubMed  Google Scholar 

  • Krakowski M, Czobor P, Volavka J (1997) Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Res 71(1):19–26

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41

    Article  CAS  PubMed  Google Scholar 

  • Mamo DC (2007) Caring for the suicidal patient: an evidence-based approach. Can J Psychiatry 52(Suppl 1):59S–70S

    PubMed  Google Scholar 

  • Meltzer HY (1999) Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry 60(Suppl 12):47–50

    CAS  Google Scholar 

  • Meltzer HY (2002) Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 4(4):279–283

    Article  PubMed  Google Scholar 

  • Meltzer HY, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152(2):183–190

    Article  CAS  PubMed  Google Scholar 

  • Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60(1):82–91

    Article  CAS  PubMed  Google Scholar 

  • Min JY, Min KB (2015) Suicide behaviors and health-related quality of life: results from the Korean community health survey of 393,073 adults. J Psychiatry 18:214. doi:10.1172/Psychatry.1000214

  • Minzenberg MJ, Lesh TA, Niendam TA, Yoon JH, Rhoades RN, Carter CS (2014) Frontal cortex control dysfunction related to long-term suicide risk in recent-onset schizophrenia. Schizophr Res 157(1–3):19–25

    Article  PubMed  Google Scholar 

  • Modai I, Hirschmann S, Rava A, Kurs R, Barak P, Lichtenberg P et al (2000) Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 20(3):325–327

    Article  CAS  PubMed  Google Scholar 

  • Modestin J, Boker W (1992) Neuroleptic therapy and suicide – review of the literature and personal results. Fortschr Neurol Psychiatr 60(4):154–162

    Article  CAS  PubMed  Google Scholar 

  • Modestin J, Dal Pian D, Agarwalla P (2005) Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J Clin Psychiatry 66(4):534–538

    Article  CAS  PubMed  Google Scholar 

  • Montgomery SA, Montgomery D (1982) Pharmacological prevention of suicidal behaviour. J Affect Disord 4(4):291–298

    Article  CAS  PubMed  Google Scholar 

  • Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E et al (2006) Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 163(5):833–838

    Article  PubMed  Google Scholar 

  • Palmer DD, Henter ID, Wyatt RJ (1999) Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry 60(Suppl 2):100–103; discussion 11–16

    PubMed  Google Scholar 

  • Planansky K, Johnston R (1971) The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatr Scand 47(4):473–483

    Article  CAS  PubMed  Google Scholar 

  • Popovic D, Benabarre A, Crespo JM, Goikolea JM, Gonzalez-Pinto A, Gutierrez-Rojas L et al (2014) Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. Acta Psychiatr Scand 130(6):418–426

    Article  CAS  PubMed  Google Scholar 

  • Potkin SG, Alphs L, Hsu C, Krishnan KR, Anand R, Young FK et al (2003) Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry 54(4):444–452

    Article  PubMed  Google Scholar 

  • Randall JR, Walld R, Finlayson G, Sareen J, Martens PJ, Bolton JM (2014) Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatry 59(10):531–538

    PubMed  PubMed Central  Google Scholar 

  • Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X (2008) Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69(8):1228–1336

    Article  CAS  PubMed  Google Scholar 

  • Reutfors J, Bahmanyar S, Jonsson EG, Brandt L, Boden R, Ekbom A et al (2013) Medication and suicide risk in schizophrenia: a nested case-control study. Schizophr Res 150(2–3):416–420

    Article  PubMed  Google Scholar 

  • Rissanen I, Jaaskelainen E, Isohanni M, Koponen H, Joukamaa M, Alaraisanen A et al (2012) Use of antipsychotic medication and suicidality – the Northern Finland Birth Cohort 1966. Hum Psychopharmacol 27(5):476–485

    Article  CAS  PubMed  Google Scholar 

  • Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y (2004) Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 24(6):582–591

    Article  CAS  PubMed  Google Scholar 

  • Sandyk R, Kay SR, Awerbuch GI, Iacono RP (1991) Risk factors for neuroleptic-induced movement disorders. Int J Neurosci 61(3–4):149–188

    Article  CAS  PubMed  Google Scholar 

  • Seemuller F, Schennach R, Mayr A, Musil R, Jager M, Maier W et al (2012) Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol 32(5):694–698

    Article  PubMed  Google Scholar 

  • Sernyak MJ, Desai R, Stolar M, Rosenheck R (2001) Impact of clozapine on completed suicide. Am J Psychiatry 158(6):931–937

    Article  CAS  PubMed  Google Scholar 

  • Siris SG (2001) Suicide and schizophrenia. J Psychopharmacol 15(2):127–135

    Article  CAS  PubMed  Google Scholar 

  • Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y et al (1998) Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 21(4):245–250

    CAS  PubMed  Google Scholar 

  • Storosum JG, van Zwieten BJ, Wohlfarth T, de Haan L, Khan A, van den Brink W (2003) Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry 60(4):365–368

    Article  PubMed  Google Scholar 

  • Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ (1999) Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 156(8):1164–1169

    CAS  PubMed  Google Scholar 

  • Suttajit S, Srisurapanont M, Xia J, Maneeton B, Maneeton N (2013) Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev 5:CD007815

    PubMed  Google Scholar 

  • Taiminen TJ, Kujari H (1994) Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. Acta Psychiatr Scand 90(4):247–251

    Article  CAS  PubMed  Google Scholar 

  • Thomas KL, Jiang Y, McCombs JS (2015) Clozapine revisited: impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Ann Clin Psychiatry: Off J Am Acad Clin Psychiatr 27(2):90–99

    Google Scholar 

  • Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333(7561):224

    Article  PubMed  PubMed Central  Google Scholar 

  • Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620–627

    Article  PubMed  Google Scholar 

  • Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6):603–609

    Article  PubMed  Google Scholar 

  • Ulcickas Yood M, Delorenze G, Quesenberry CP Jr, Tsai AL, Phillips S, Willey VJ et al (2010) Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiol Drug Saf 19(11):1124–1130

    Article  PubMed  Google Scholar 

  • Van Oekelen D, Luyten WH, Leysen JE (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72(22):2429–2449

    Article  PubMed  Google Scholar 

  • Van Putten T, May RP (1978) “Akinetic depression” in schizophrenia. Arch Gen Psychiatry 35(9):1101–1107

    Article  PubMed  Google Scholar 

  • Vangala VR, Brown ES, Suppes T (1999) Clozapine associated with decreased suicidality in bipolar disorder: a case report. Bipolar Disord 1(2):123–124

    Article  CAS  PubMed  Google Scholar 

  • Viner MW, Chen Y, Bakshi I, Kamper P (2003) Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol 23(1):104–106

    Article  PubMed  Google Scholar 

  • Walker AM, Lanza LL, Arellano F, Rothman KJ (1997) Mortality in current and former users of clozapine. Epidemiology 8(6):671–677

    Article  CAS  PubMed  Google Scholar 

  • Warnez S, Alessi-Severini S (2014) Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 14:102

    Article  PubMed  PubMed Central  Google Scholar 

  • Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A et al (2011) Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. J Clin Psychiatry 72(4):548–555

    Article  CAS  PubMed  Google Scholar 

  • Wilkinson G, Bacon NA (1984) A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics. Psychol Med 14(4):899–912

    Article  CAS  PubMed  Google Scholar 

  • Yassa R, Jones BD (1985) Complications of tardive dyskinesia: a review. Psychosomatics 26(4):305–307, 10, 12–3

    Article  CAS  PubMed  Google Scholar 

  • Yerevanian BI, Choi YM (2013) Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord 15(5):594–621

    Article  PubMed  Google Scholar 

  • Yerevanian BI, Koek RJ, Mintz J (2007) Bipolar pharmacotherapy and suicidal behavior part 3: impact of antipsychotics. J Affect Disord 103(1–3):23–28

    Article  CAS  PubMed  Google Scholar 

  • Zalsman GT, Lewy T, Shoval G (2008) Interacion of child and family leading to suicidal behavior. Psychiatr Clin North Am 31:237–246

    Google Scholar 

  • Zeng R, Cohen LJ, Tanis T, Qizilbash A, Lopatyuk Y, Yaseen ZS et al (2015) Assessing the contribution of borderline personality disorder and features to suicide risk in psychiatric inpatients with bipolar disorder, major depression and schizoaffective disorder. Psychiatry Res 226(1):361–367

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, University of Oviedo, Oviedo, Spain

    Celso Iglesias MD, PhD, Pilar A. Sáiz MD, PhD, Paz García-Portilla MD, PhD & Julio Bobes MD, PhD

Authors
  1. Celso Iglesias MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pilar A. Sáiz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paz García-Portilla MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Julio Bobes MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pilar A. Sáiz MD, PhD .

Editor information

Editors and Affiliations

  1. Academic Hospital of Montpellier, University of Montpellier, Montpellier, France

    Philippe Courtet

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Iglesias, C., Sáiz, P.A., García-Portilla, P., Bobes, J. (2016). Antipsychotics. In: Courtet, P. (eds) Understanding Suicide. Springer, Cham. https://doi.org/10.1007/978-3-319-26282-6_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26282-6_26

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26280-2

  • Online ISBN: 978-3-319-26282-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation